STRC Research

Migalastat Dosing-Cycle Principle

3 min read

Migalastat Dosing-Cycle Principle

Distilled from DR1 — Pharmacochaperone Clinical Precedents §2. Companion to Pharmacochaperone Residence Time Criterion: residence time has both a floor (long enough for QC traversal) and a ceiling (short enough to free the target at site of action).

The principle

Migalastat (1-deoxygalactonojirimycin, iminosugar, MW 163.2) is a competitive active-site inhibitor of α-galactosidase A. The chaperone mechanism only works because:

  1. At neutral ER pH (~7.4): Migalastat binds the active site of mutant α-Gal A, masks exposed hydrophobic residues, lowers folded-state ΔG, rescues the protein from ERAD.
  2. At acidic lysosomal pH (~4.0): local Gb3 substrate concentration is high and the protonation state of the iminosugar shifts, dropping affinity. Migalastat dissociates, freeing the rescued enzyme to do its catalytic job.
  3. Dosing regimen 150 mg QOD (every other day, oral): plasma drug troughs ensure periods of unimpeded enzyme function, even if pH-driven dissociation is incomplete.

The drug is approved (FDA 2018, EMA 2016) only on patients with “amenable mutations” — defined by an FDA-validated HEK-293 in vitro assay measuring (a) immature/mature glycoform ratio shift on Western and (b) thermal stabilization on DSF.

The whole construction depends on a microenvironmental gradient (pH between ER and lysosome) that drives off-rate at the right place.

The negative case — Afegostat

DR1 — Pharmacochaperone Clinical Precedents §6 — Afegostat (AT-2101, isofagomine), an iminosugar β-glucocerebrosidase chaperone for Gaucher disease, failed Phase 2 with perfect target engagement. White-blood-cell GCase activity rose 3.5×; clinical biomarkers (platelet count, hemoglobin, chitotriosidase) did not move. Post-mortem: Afegostat retained high affinity for the active site at lysosomal pH and acted as a permanent inhibitor of the rescued enzyme.

Lesson: the “chaperone trap” is real and binary. A drug that rescues trafficking but does not release at the site of action is functionally an inhibitor masquerading as a chaperone.

Why this matters for H01 — STRC has no pH gradient

STRC is extracellular. After ER folding and Golgi trafficking, mature stereocilin is secreted into the cochlear extracellular space and crosslinked into the tectorial membrane and stereocilia tip-link / horizontal-top-connector environment. There is no ER → lysosome pH switch on its trafficking path.

This eliminates the Migalastat-style microenvironmental dissociation strategy. The H01 lead aq3_adamantyl_CONHOH_-Cl therefore must satisfy one of:

  1. Tuned intrinsic k_off — slow enough for ER QC traversal (tens of min to hours per Pharmacochaperone Residence Time Criterion), fast enough that the drug clears before reaching the tectorial-membrane crosslinking environment, where bound drug could disrupt structural function.
  2. Allosteric binding — at a site distinct from any known stereocilin-stereocilin or stereocilin-CEACAM16/OTOG/OTOGL contact interface. K1141 is in the FN3-like domain pocket; whether this interface participates in the tectorial-membrane crosslink is not yet checked in any H01 phase.

The choice between (1) and (2) is a fork H01 has not made explicit. Both are testable; both bear consequences for v5.3 design.

Operational implication

Concrete next-step additions:

  • Map all known stereocilin-stereocilin and stereocilin-partner interfaces onto the AF3 E1659A model. Test whether K1141 pocket overlaps with any (CEACAM16, OTOG, OTOGL contact patches per published interactome).
  • τRAMD on the lead (Pharmacochaperone Residence Time Criterion already proposed) gains a second axis of interpretation: a residence time too long (e.g., > 24 h) on extracellular STRC is a liability, not an asset. The acceptable window is roughly bounded below by ER transit (~30 min – 4 h) and above by tectorial membrane assembly time (~hours to days, Hair Cell Biophysical Reference Table).

Connections

Graph View

Backlinks